Scribe Therapeutics

We're pleased to announce: 📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction 📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150

Next Tuesday, we’re presenting at #GENESRC, the Genome Engineering: Research and Applications conference hosted by @FASEBorg. Details below on our session about increasing the potency of CasX-based editors to enable safer, more effective #CRISPR-based therapeutics. #FASEB

Watch the @BloombergTV interview to learn more about where CRISPR stands today and what comes next for genetic medicine ⬇️ bloomberg.com/news/videos/20… Read more in @business ⬇️ bloomberg.com/news/articles/… #CRISPR #GeneEditing

Dr. Jennifer Doudna, Nobel laureate and Scribe co-founder, shares her vision for the future of gene editing with @bbgoriginals host @emilychangtv. Full video and article links in thread 🧵

Read @TheEconomist feature to learn more about our CRISPR-based epigenetic silencing technology. Scribe is now a clinical-stage company advancing STX-1150, our lead investigational therapy targeting PCSK9, in a Phase 1 study: economist.com/science-and-te… #CRISPR #CVD #GeneticMedicine

🧬 @TheEconomist breaks down epigenetic medicine, the next frontier for CRISPR-based therapies: → How #EpigeneticEditing works → Potential safety advantages → How genes like PCSK9 that Scribe is focused on could be targeted to reduce LDL cholesterol and cardiovascular risk

This Juneteenth, we invited our Alameda neighbor Sips Global Tea to share their knowledge and collection of global teas sourced from Africa, Asia, South America, & Europe with our team. Thanks for leading us through the craft and culture of tea blending for a day of community 🍵

Our #CRISPR-based #GeneEditing therapies STX-1200 and STX-1400 are designed for single-dose, durable lowering of key lipid drivers of ASCVD: Lp(a) and triglycerides, respectively. Read our release here: businesswire.com/news/home/2026…

We’re excited to share that @CIRMnews has awarded Scribe more than $25 million through its Preclinical Development Program to accelerate the advancement of two preclinical programs targeting cardiovascular and metabolic disease. Press release in thread 📣

At #BIO2026, meet the BD team behind Scribe’s collaborations with leading pharma companies like Lilly and Sanofi. Set up a meeting using the @IAmBiotech portal to learn how partnerships broaden and accelerate the impact of our engineered #CRISPR tech 👇 partner.bio.org/conference/86/…

Our go-to recipe for a team brunch? Good food and even better company. At Scribe, we have it down to a science. 🧑‍🍳

In Precision Medicine Online, read about our first clinical trial for STX-1150, our novel, in vivo therapy designed to epigenetically silence PCSK9 and deliver sustained LDL-C reduction after a single dose – without permanently altering DNA. 📖 precisionmedicineonline.com/regulatory-new…

Read the full report in our press release: businesswire.com/news/home/2026… @EASCongress #CRISPR #EpigeneticEditing #CVD

At #EASCongress2026, we presented late-breaking preclinical data on our lead cardiometabolic program STX-1150. These data support STX-1150 as a clinical-stage epigenetic silencing therapy designed to achieve years of LDL-C lowering after a single dose. Study highlights below ⬇️

#EASCongress2026 has kicked off! A late-breaking oral presentation from our CEO @BenjaminLOakes will showcase preclinical data for STX-1150, our epigenetic silencing therapy that’s designed for durable LDL-C reduction & now in the clinic. Thanks to @EASCongress for featuring it!

📰 @theheraldsun article: heraldsun.com.au/health/unbelie… 🎤 If you're at #EASCongress2026 on Monday, May 25, check out the late-breaking oral presentation by Scribe co-founder and CEO @BenjaminLOakes, highlighting our preclinical data for STX-1150: businesswire.com/news/home/2026… @EASCongress

In @theheraldsun, Dr. Stephen Nicholls of @MonashVHI, Victorian Heart Hospital, and the PI leading Scribe's clinical trial shares his perspective on our epigenetic silencing drug STX-1150 and the need for improved therapies for cardiovascular disease. Links in thread ⬇️

More details on our clinical trial and commentary from Scribe CEO @BenjaminLOakes and Principal Investigator Stephen Nicholls (@MonashVHI, Victorian Heart Hospital, @MonashUni, @MonashHealth): businesswire.com/news/home/2026… #CVD #HeartHealth #CRISPR #EpigeneticEditing

STX-1150 is designed to epigenetically silence PCSK9 in the liver and deliver sustained LDL-C reduction after a single dose without permanently altering DNA, with the goal of enabling early and durable ASCVD risk reduction in patients. Link to our full announcement below ❤️‍🩹

Announcing our first clinical trial. Scribe has secured regulatory clearance from Australia’s @TGAgovau to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD). Details🧵